Placental transfer of darunavir in an ex vivo human cotyledon perfusion model

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5617-5620

  Mandelbrot, Laurent ^a,b   Duro, Dominique ^a   Belissa, Emilie ^c   Peytavin, Gilles ^c  

^a HÔPITAL LOUIS MOURIER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PHENAZONE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; SULFONAMIDE;

ARTICLE; BLOOD PLACENTA BARRIER; COTYLEDON; DRUG BIOAVAILABILITY; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; NONHUMAN; PLACENTA PERFUSION; PLACENTAL TRANSFER; PRIORITY JOURNAL; PROTEIN BINDING; STEADY STATE; TANDEM MASS SPECTROMETRY; THIRD TRIMESTER PREGNANCY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VIRAL CLEARANCE; FEMALE; FETOMATERNAL TRANSFUSION; METABOLISM; PLACENTA; PREGNANCY; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; DARUNAVIR; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MATERNAL-FETAL EXCHANGE; PLACENTA; PREGNANCY; SULFONAMIDES;

EID: 84906096690     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03184-14     Document Type: Article

References (35)

1. Tubiana R, Matheron S, Le Chenadec J, Dollfus C, Faye A, Blanche S, Rouzioux C, Benhammou V, Mandelbrot L, Warszawski J. 2011. Extremely low risk of mother-to-child transmission of HIV in women starting HAART before pregnancy in the French perinatal cohort (ANRS EPF CO1/11). 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 27 February to 2 March 2011.
2. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, Faye A, Burgard M, Rouzioux C, Mandelbrot L. 2008. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French perinatal cohort. AIDS 22: 289 -299. http://dx.doi.org/10.1097/QAD.0b013e3282f3d63c.
3. Morlat P. 2013. Prise en charge médicale des personnes vivant avec le VIH. Recommandations du groupe d'experts-Rapport 2013. http://www.sante. gouv.fr/IMG/pdf/Rapport-Morlat-2013-Mise-en-ligne.pdf.
4. U.S. Public Health Service. 2013. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/contentfiles/lvguidelines/Peri-Recommendations.pdf.
5. Reference deleted.
6. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru- Vigneron N, Lacroix C, Rouzioux C, Mandelbrot L, Desguerre I, Rotig A, Mayaux MJ, Delfraissy JF. 1999. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354: 1084-1089. http://dx.doi.org/10.1016/S0140-6736(99)07219-0.
7. Heidari S, Mofenson L, Cotton MF, Marlink R, Cahn P, Katabira E. 2011. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J. Acquir. Immune Defic. Syndr. 57:290-296. http://dx.doi.org/10.1097/QAI.0b013e318221c56a.
8. Sibiude J, Mandelbrot L, Blanche S, Chenadec JL, Bouallag-Bonnet N, Faye A, Dollfus C, Tubiana R, Khoshnood B, Warszawski J 2014. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study. PLoS Med. 11: e1001635. http://dx.doi.org/10. 1371/journal.pmed.1001635.
9. Chougrani I, Luton D, Matheron S, Mandelbrot L, Azria E. 2013. Safety of protease inhibitors in HIV-infected pregnant women. HIV AIDS (Auckl.) 5:253-262. http://dx.doi.org/10.2147/HIV.S33058.
10. Mandelbrot L, Mazy F, Floch-Tudal C, Meier F, Azria E, Crenn-Hebert C, Treluyer JM, Herinomenzanahary E, Ferreira C, Peytavin G. 2011. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia. Eur. J. Obstet. Gynecol. Reprod. Biol. 157:18-21. http://dx.doi.org/10.1016/j.ejogrb.2011.02.005.
11. Simon A, Warszawski J, Kariyawasam D, Le Chenadec J, Benhammou V, Czernichow P, Foissac F, Laborde K, Treluyer JM, Firtion G, Layouni I, Munzer M, Bavoux F, Polak M, Blanche S. 2011. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 306: 70-78. http://dx.doi.org/10.1001/jama.2011. 915.
12. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, Mc-Sherry GD, O'Sullivan MJ, Van Dyke RB, Jimenez E, Rouzioux C, Flynn PM, Sullivan JL. 1996. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 335:1621-1629. http://dx.doi.org/10.1056/NEJM199611283352201. (Pubitemid 26392726)
13. Hirt D, Urien S, Ekouevi DK, Rey E, Arrive E, Blanche S, Amani-Bosse C, Nerrienet E, Gray G, Kone M, Leang SK, McIntyre J, Dabis F, Treluyer JM, Anrs. 2009. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin. Pharmacol. Ther. 85:182-189. http://dx.doi.org/10.1038/clpt.2008.201.
14. Hirt D, Urien S, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Treluyer JM. 2007. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples. Br. J. Clin. Pharmacol. 64:634-644. http://dx.doi.org/10.1111/j.1365-2125.2007.02885.x. (Pubitemid 47568807)
15. Gavard L, Beghin D, Forestier F, Cayre Y, Peytavin G, Mandelbrot L, Farinotti R, Gil S. 2009. Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs: example of a protease inhibitor of HIV: nelfinavir. Eur. J. Obstet. Gynecol. Reprod. Biol. 147: 157-160. http://dx.doi.org/10.1016/j.ejogrb.2009.08.007.
16. Schneider H, Panigel M, Dancis J. 1972. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am. J. Obstet. Gynecol. 114:822-828.
17. Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L. 2001. Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am. J. Obstet. Gynecol. 185:178-181. http://dx.doi.org/10.1067/ mob.2001.113319. (Pubitemid 32681815)
18. Vinot C, Gavard L, Treluyer JM, Manceau S, Courbon E, Scherrmann JM, Decleves X, Duro D, Peytavin G, Mandelbrot L, Giraud C. 2013. Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression. Antimicrob. Agents Chemother. 57:1415-1420. http://dx.doi.org/10.1128/AAC.01821-12.
19. Jung BH, Rezk NL, Bridges AS, Corbett AH, Kashuba AD. 2007. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 21:1095-1104. http://dx.doi.org/10.1002/bmc.865. (Pubitemid 47490320)
20. Challier JC, D'Athis P, Guerre-Millo M, Nandakumaran M. 1983. Flow-dependent transfer of antipyrine in the human placenta in vitro. Reprod. Nutr. Dev. 23:41-50. http://dx.doi.org/10.1051/rnd:19830104. (Pubitemid 13036539)
21. Tie Y, Boross PI, Wang YF, Gaddis L, Hussain AK, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT. 2004. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J. Mol. Biol. 338:341-352. http://dx.doi.org/10.1016/j.jmb.2004.02.052. (Pubitemid 38447090)
22. Boffito M, Jackson A, Amara A, Back D, Khoo S, Higgs C, Seymour N, Gazzard B, Moyle G. 2011. Pharmacokinetics of once-daily darunavirritonavir and atazanavir-ritonavir over 72 hours following drug cessation. Antimicrob. Agents Chemother. 55:4218-4223. http://dx.doi.org/10.1128/AAC.01747-10.
23. + women, abstr. 1011. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5 to 8 March 2012.
24. Ivanovic J, Bellagamba R, Nicastri E, Signore F, Vallone C, Tempestilli M, Tommasi C, Mazzitelli L, Narciso P. 2010. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. AIDS 24:1083-1084. http://dx.doi.org/10.1097/QAD. 0b013e32833653b2.
25. Pinnetti C, Tamburrini E, Ragazzoni E, De Luca A, Navarra P. 2010. Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1. Antivir. Ther. 15:127-129. http://dx.doi.org/10.3851/IMP1473.
26. Zorrilla CD, Wright R, Osiyemi OO, Yasin S, Baugh B, Brown K, Coate B, Verboven P, Mrus J, Falcon R, Kakuda TN. 2014. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Med. 15:50-56. http://dx.doi.org/10.1111/hiv.12047.
27. Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, Ruggeri M, Suter F. 2007. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 21:2409-2415. http://dx.doi.org/ 10.1097/QAD.0b013e32825a69d1. (Pubitemid 350145172)
28. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS. 2006. Reduced lopinavir exposure during pregnancy. AIDS 20:1931-1939. http://dx.doi.org/10.1097/01.aids. 0000247114.43714.90. (Pubitemid 44427610)
29. Chappuy H, Treluyer JM, Rey E, Dimet J, Fouche M, Firtion G, Pons G, Mandelbrot L. 2004. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am. J. Obstet. Gynecol. 191:558-562. http://dx.doi.org/10.1016/j.ajog.2004.01.034. (Pubitemid 39178714)
30. Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, Mofenson L, Culnane M, Connor J, Sullivan JL. 2002. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr. Infect. Dis. J. 21:835-838. http://dx.doi.org/10.1097/00006454-200209000-00010.
31. Gavard L, Gil S, Peytavin G, Ceccaldi PF, Ferreira C, Farinotti R, Mandelbrot L. 2006. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am. J. Obstet. Gynecol. 195:296-301. http://dx.doi.org/10.1016/j.ajog.2006.01.017. (Pubitemid 43927527)
32. Ceccaldi PF, Gavard L, Mandelbrot L, Rey E, Farinotti R, Treluyer JM, Gil S. 2009. Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model. Obstet. Gynecol. Int. 2009:726593. http://dx.doi.org/10.1155/2009/726593.
33. Gil S, Saura R, Forestier F, Farinotti R. 2005. P-glycoprotein expression of the human placenta during pregnancy. Placenta 26:268-270. http://dx.doi.org/10.1016/j.placenta.2004.05.013. (Pubitemid 40247016)
34. Casey BM, Bawdon RE. 1998. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am. J. Obstet. Gynecol. 179:758-761. http://dx.doi.org/10.1016/S0002-9378(98)70078-X. (Pubitemid 28447260)
35. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, Natureeba P, Luwedde FA, Achan J, Kamya MR, Havlir DV, Cohan D, Prevention of Malaria and HIV Disease in Tororo (PROMOTE) Study. 2013. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J. Acquir. Immune Defic. Syndr. 63:578-584. http://dx.doi.org/10.1097/QAI. 0b013e31829c48ad.